{
    "organizations": [],
    "uuid": "db6415a76a84b5df7dbaa3431d10766faa3d8559",
    "author": "",
    "url": "https://www.reuters.com/article/brief-gemphire-announces-initiation-of-p/brief-gemphire-announces-initiation-of-phase-2a-clinical-trial-of-pediatric-nafld-idUSASB0C3B8",
    "ord_in_thread": 0,
    "title": "BRIEF-Gemphire Announces Initiation Of Phase 2A Clinical Trial Of Pediatric NAFLD",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 31 (Reuters) - Gemphire Therapeutics Inc:\n* GEMPHIRE ANNOUNCES INITIATION OF PHASE 2A CLINICAL TRIAL OF GEMCABENE IN PEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)\n* GEMPHIRE THERAPEUTICS INC - ‍TOP LINE RESULTS FROM PEDIATRIC NAFLD TRIAL ARE EXPECTED IN EARLY 2019​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-31T23:52:00.000+02:00",
    "crawled": "2018-02-01T00:08:08.019+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "gemphire",
        "therapeutic",
        "inc",
        "gemphire",
        "announces",
        "initiation",
        "phase",
        "2a",
        "clinical",
        "trial",
        "gemcabene",
        "pediatric",
        "fatty",
        "liver",
        "disease",
        "nafld",
        "gemphire",
        "therapeutic",
        "inc",
        "line",
        "result",
        "pediatric",
        "nafld",
        "trial",
        "expected",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}